3 results
Approved WMOCompleted
The primary objective of the study is to evaluate the safety, tolerability, PK, and PD of AL002 administered in single ascending doses in healthy participants and multiple doses in participants with mild to moderate AD.
Approved WMOCompleted
Primary:To demonstrate the non-inferior antiviral activity of CAB LA + RPV LA every two months compared to a BIK single tablet regimen administered once daily over 12 months in suppressed HIV-1 infected antiretroviral therapy (ART)-experienced…
Approved WMOPending
To evaluate the efficacy of AL002 in participants with Early AD in delaying disease progression compared to standard of care